Drug intelligence / Profile preview

AG1001

Development stage: Unknown
Lead developer: Beijing Aige Stem Cell Technology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

AG1001 is a human adipose-derived mesenchymal stem cell (hAD-MSC) injection developed by Beijing Aige Stem Cell Technology. It is designed for the treatment of systemic sclerosis (SSc), a chronic autoimmune disease characterized by skin and internal organ fibrosis. Mesenchymal stem cells are known for their immunomodulatory and anti-fibrotic properties, which help in reducing inflammation and promoting tissue repair. AG1001 received clinical trial implied approval from the China NMPA in June 2023 and has completed Phase I clinical trials. A Phase II study is scheduled to initiate in the second quarter of 2025.

Other names: 人脂肪间充质干细胞注射液Human Adipose Mesenchymal Stem Cell Injection

Beyond the preview

Go deeper on AG1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG1001.

Explore the full profile